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Abstract
Hepatocellular carcinoma (HCC) represents a global 
health problem. Infections with hepatitis B or C virus, 
non-alcoholic steatohepatitis disease, alcohol abuse, or 
dietary exposure to aflatoxin are the major risk factors 
to the development of this tumor. Regardless of the 
carcinogenic insult, HCC usually develops in a context 
of cirrhosis due to chronic inflammation and advanced 
fibrosis. Galectins are a family of evolutionarily-con-
served proteins defined by at least one carbohydrate 
recognition domain with affinity for β-galactosides and 
conserved sequence motifs. Here, we summarize the 
current literature implicating galectins in the pathogen-
esis of HCC. Expression of “proto-type” galectin-1, “chi-
mera-type” galectin-3 and “tandem repeat-type” ga-
lectin-4 is up-regulated in HCC cells compared to their 
normal counterparts. On the other hand, the “tandem-
repeat-type” lectins galectin-8 and galectin-9 are down-
regulated in tumor hepatocytes. The abnormal expres-
sion of these galectins correlates with tumor growth, 
HCC cell migration and invasion, tumor aggressiveness, 
metastasis, postoperative recurrence and poor progno-
sis. Moreover, these galectins have important roles in 
other pathological conditions of the liver, where chronic 
inflammation and/or fibrosis take place. Galectin-based 
therapies have been proposed to attenuate liver pathol-
ogies. Further functional studies are required to delin-
eate the precise molecular mechanisms through which 
galectins contribute to HCC.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
Key words: Galectins; Hepatocellular carcinoma; 
Inflammation-associated liver injury; Hepatitis B or C 
virus infection-associated hepatocellular carcinoma; 
Fibrosis-related liver pathologies
Core tip: Galectins, a family of glycan-binding proteins, 
are involved in the pathogenesis of hepatocellular carci-
noma (HCC). Up-regulation of galectin-1, galectin-3 and 
galectin-4 is observed in HCC cells, whereas galectin-8 
and galectin-9 appear to be down-regulated in tumor 
hepatocytes. This altered expression correlates with 
tumor growth, HCC cell migration and invasion, tumor 
aggressiveness, metastasis, postoperative recurrence 
and poor prognosis. These galectins are also implicated 
in inflammation- and fibrosis-related liver pathologies.
Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hier-
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INTRODUCTION
Hepatocellular carcinoma (HCC) represents a global 
health problem. It is the fifth most common solid tumor 
and the third cause of  cancer-related mortality per year[1]. 
HCC is most prevalent in Eastern Asia and sub-Saharan 
Africa; whereas the incidence in Europe and North 
America is considerably lower[2-4]. The etiology of  HCC 
includes major risk factors such as infection with Hepati-
tis B or C virus (HBV, HCV), alcohol abuse or dietary ex-
posure to aflatoxin[5-7]. Regardless of  the carcinogenic in-
sult, HCC usually develops in patients with cirrhosis due 
to chronic inflammation and advanced fibrosis[8]. Non-
alcoholic steatohepatitis (NASH), a metabolic disorder 
resulting from insulin resistance syndrome that underlies 
fibrosis and cirrhosis, is emerging as another important 
risk factor for HCC[9,10]. 
During the past decade the management of  HCC has 
significantly improved[11]. New advances in the field have 
led to a better knowledge and an earlier detection of  this 
disease. Additionally, current therapies such as, resec-
tion, transplantation, ablation and chemoembolization, 
have provided benefit to patients diagnosed at early HCC 
stages improving and extending their survival[12-14]. How-
ever, most patients are diagnosed at advanced stages and 
therefore, they are not amenable to surgical treatment. 
Even after resection or transplantation, the prognosis 
remains unsatisfactory due to recurrence, metastasis and 
the development of  new primary tumors[15-17].
Recent progress toward a better understanding of  
the molecular biology of  HCC has allowed the develop-
ment of  molecular targeted therapies and has shed light 
on new systemic therapies for HCC. Several intracellular 
signaling pathways involved in abnormal proliferation, 
survival, differentiation, invasion and metastasis have 
been found to be dysregulated in HCC. Clinical trials are 
currently testing the potential use of  inhibitors of  the 
Ras/Raf/mitogen-activated protein kinase/extracellular 
signal-regulated kinase (ERK), phosphatase and tensin 
homolog deleted on chromosome 10/phosphoinositide 
3-kinase (PI3K)/Akt/mammalian target of  rapamycin, 
transforming growth factor β (TGF-β), Wnt/β-catenin 
and epidermal growth factor receptor (EGFR) pathways, 
among others[18-20]. Sorafenib, a receptor tyrosine kinase 
inhibitor targeting vascular endothelial growth factor, 
platelet-derived growth factor and Raf  signaling pathways 
prolongs survival in patients with advanced unresectable 
HCC[21,22]. Simultaneously, new immunotherapy strategies 
are being developed for the treatment of  HCC, which 
could be administered in combination with conventional 
therapies in order to obtain a more favorable clinical 
outcome[23]. Undoubtedly, the approval of  oral admin-
istration of  sorafenib highlights the the importance of  
elucidating the molecular mechanisms underlying HCC 
progression for the development of  novel therapies.
Recently, there has been increasing evidence high-
lighting the involvement of  galectins, a family of  glycan-
binding proteins, in the pathogenesis of  HCC. In this 
review, we present emerging data showing that expression 
of  some members of  this family is altered in HCC cell 
lines and tissues compared to normal liver. These obser-
vations led to the proposition that galectins are potential 
prognostic biomarkers and therapeutic targets in HCC. 
We will discuss the possible roles of  these proteins in 
HCC tumor transformation, progression, aggressiveness 
and metastasis. Moreover, we will highlight the involve-
ment of  galectins in other pathological settings of  the 
liver, where chronic inflammation and/or fibrosis take 
place.
GALECTINS
Galectins are a family of  evolutionary conserved glycan-
binding proteins or lectins that recognize multiple 
N-acetyllactosamine (Galβ1,4GlcNAc) units on cell sur-
face glycoconjugates. These animal proteins are defined 
by at least one carbohydrate recognition domain (CRD) 
with affinity for β-galactosides and conserved sequence 
motifs[24]. To date, fifteen galectins have been described 
in mammals and according to their structural character-
istics they are classified into three groups: “proto-type” 
galectins (galectin-1, galectin-2, galectin-5, galectin-7, 
galectin-10, galectin-11, galectin-13, galectin-14 and ga-
lectin-15) contain one CRD and can dimerize; “tandem 
repeat-type” galectins (galectin-4, galectin-6, galectin-8, 
galectin-9 and galectin-12) contain two distinct CRD in 
tandem, connected by a linker peptide; and “chimera-
type” galectin-3 which consists of  unusual proline- and 
glycine-rich short stretches fused onto the CRD[25,26].
Some galectins (e.g., galectin-1, galectin-3 and ga-
lectin-9) are widely expressed among different tissues 
including, immune cells, endothelial and epithelial cells, 
and sensory neurons (reviewed by[27-29]); whereas other 
family members have a more restricted tissue localization 
and compartmentalization (e.g., galectin-7 is preferentially 
found in the skin, galectin-12 is abundantly expressed in 
adipose tissue, galectin-5 is restricted to rat reticulocytes, 
and galectin-10 is strongly represented in human but not 
mouse eosinophils)[27].
These lectins do not possess a signal peptide for 
export through the classical secretory pathway (Golgi-
endoplasmic reticulum); however they are secreted to 
the extracellular milieu via a non-conventional poorly 
understood secretory pathway[30-32]. For instance, non-
classical secretion of  galectin-1 has been observed in 
skeletal muscle during in vivo development and in cultured 
myoblasts during differentiation[33]. Besides, secretion of  
galectin-3 from macrophages, renal and polarized intes-
tinal epithelial cells has been detected[34,35]. There is also 
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evidence for secretion of  galectin-9 in activated Jurkat T 
cells[36] and CD4 T cells expressing galectin-9 on the cell 
surface upon T cell receptor stimulation[37].
 Through its binding to N-acetyllactosamine sequenc-
es, galectins form multivalent complexes with cell surface 
glycoconjugates and thus, transmit signals inside the 
cell[38-40]. Remarkably, it has also been demonstrated that 
galectin-1 can be internalized by Jurkat T cells in a carbo-
hydrate-dependent mechanism, following dual pathways 
involving clathrin-coated vesicles and raft-dependent en-
docytosis[41]. Within the intracellular milleu, galectins bind 
to their ligands preferentially through protein-protein in-
teractions, and regulate intracellular processes, including 
mRNA splicing, cell cycle progression, apoptosis, and cell 
proliferation[42].
Galectins have emerged as pivotal regulators of  cel-
lular physiology. Over the past decade, multiple biologi-
cal functions have been reported for this protein family 
including roles in cell adhesion, migration, cytokine syn-
thesis, and survival[43,44]. In fact, different members of  the 
family have shown critical roles as mediators of  acute and 
chronic inflammation[45,46]. Galectins are often aberrantly 
expressed in many different tumor types including as-
trocytoma, melanoma and prostate, thyroid, colon, head 
and neck, bladder, kidney, stomach, lung, bladder, uterine, 
breast and ovary carcinomas[27,47,48]. Moreover, mounting 
evidence indicates that these proteins play fundamental 
roles in cancer biology including tumor transformation, 
tumor growth, angiogenesis, migration, metastasis and 
tumor-immune escape[49-52]. Given these pleiotropic activi-
ties in the tumor microenvironment, galectins are being 
increasingly recognized as molecular targets for innova-
tive cancer therapy[26,52-56]. 
In this review, we summarize the current data im-
plicating galectins in HCC. Particularly, we focus our 
discussion on selected members of  the family, including 
galectin-1, galectin-3, galectin-4, galectin-8 and galectin-9, 
which roles in HCC biology have been demonstrated.
GALECTIN-1
The first protein discovered within the galectin family 
was galectin-1. This galectin possesses one CRD and can 
form homodimers via non-covalent binding, which con-
fers the ability to cross-link specific glycoconjugates[26,28]. 
Galectin-1 displays features of  typical cytoplasmic pro-
teins; it has been described in nucleus and cytoplasm and 
can translocate to the intracellular face of  cellular mem-
branes. Although galectin-1 lacks a recognizable secretion 
signal sequence, it is secreted through a non-conventional 
secretory pathway[31,32]; thus being detected on the extra-
cellular side of  cellular membranes as well as in the extra-
cellular matrices (ECM) of  various normal and neoplastic 
tissues[57]. 
While the role of  galectin-1 within the intracellular 
milieu is often independent of  its lectin activity, its extra-
cellular functions are mostly dependent on the binding 
to N-acetyllactosamine units on cell surface glycocon-
jugates[28]. Intracellularly, galectin-1 is engaged in funda-
mental processes such as pre-mRNA splicing; and also 
it interacts with oncogenic H-RAS and contributes to its 
membrane anchorage, evidencing a key role for this ga-
lectin in driving tumor transformation (reviewed by[49,58]). 
In the extracellular space, galectin-1 binds to glycoconju-
gates on the cell surface, including different members of  
the integrin family and glycoproteins of  the ECM such 
as laminin and fibronectin[59,60]. It is likely that the local 
abundance of  galectin-1 in the tumor microenvironment 
may play a critical role during attachment or detachment 
of  cancer cells throughout cancer progression[43]. Fur-
thermore, galectin-1 promotes cell migration, a function 
that correlates with the ability of  this protein to influence 
tumor progression, invasion and angiogenesis. However, 
the biological roles of  galectin-1 appear to be tissue-spe-
cific as it also decreases cell migration of  most immune 
cells providing a rational basis for its anti-inflammatory 
properties[43,45,55,61]. 
Expression of  galectin-1 has been well documented 
in many different tumor types including astrocytoma, 
melanoma and prostate, thyroid, colon, bladder and ovary 
carcinomas[57,62]. Moreover, preferential accumulation of  
galectin-1 in the peritumoral stroma has been described 
for thyroid, head and neck, colon, ovary and prostate 
carcinoma[57]. Functions of  galectin-1 during tumor pro-
gression have been largely documented in the literature. 
High levels of  galectin-1 correlate with aggressiveness 
of  tumors[63-67], and the acquisition of  a metastatic phe-
notype[68-71]. This lectin plays a fundamental role in tumor 
angiogenesis by modulating endothelial cell biology[72,73] 
and its expression is induced by hypoxia[74,75]. Importantly, 
galectin-1 has been proposed to be a major immunosup-
pressive factor which contributes to tumor immunoeva-
sive programs[76,77]. In fact, galectin-1 expression by tu-
mor cells or by their surrounding stroma can regulate the 
function, fate and viability of  infiltrating tumor-specific T 
cells[78]. 
Galectin-1 in HCC and in inflammation-associated liver 
injury
Galectin-1 gene (LGALS1) regulation was extensively 
studied using the well characterized system hepatoma 
x fibroblast hybrids. Activation of  gene expression was 
achieved by treatment of  galectin-1-non-expressing cells 
with the DNA demethylating agent azacytidine. The 
methylation status of  the galectin-1 gene promoter was 
identified as a central mechanism that controls gene ex-
pression in normal tissues and also in transformed cells 
and tumors[27]. 
While in normal liver galectin-1 is expressed at low 
constitutive levels, in HCC its expression is dramatically 
up-regulated[79-82]. Gene expression profiling of  normal 
and HCC human tissues using cDNA microarrays al-
lowed the identification of  LGALS1 as one of  the hall-
mark genes that are over-expressed in HCC, a phenom-
enon which was further confirmed by RT-PCR[79]. 
Kondoh et al[80] elucidated the molecular mechanism 
governing LGALS1 gene expression in liver malignancy. 
This group investigated the methylation states of  the 
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Although over-expression of  galectin-1 was observed 
in HCC in vivo as well as in vitro, the precise function of  
this endogenous lectin in liver pathophysiology remained 
uncertain for many years. However, emerging findings 
shed light to the role to the leading role of  galectin-1 in 
HCC development and progression. Spano et al[81] report-
ed that galectin-1 expression was significantly increased 
in HCC samples from patients with metastatic disease 
compared to those harboring a non-metastatic primary 
tumor. However, no significant associations were found 
with other parameters, although a trend toward an asso-
ciation between increased galectin-1 expression in HCC 
and vascular invasion was observed. Moreover, galectin-1 
expression profile was also examined in human HuH-7 
and JHH-6 HCC cells and human normal liver, cirrhotic 
tissue and HCC specimens using tissue microarrays. In 
all cases, increased expression of  the LGALS1 gene was 
confirmed in HCC. Furthermore, immunohistochemical 
analysis revealed a preferential accumulation of  galectin-1 
galectin-1 gene promoter in human HCC and adjacent 
non-tumor liver tissue, and in different HCC cell lines. 
Analysis of  the methylation profile revealed that certain 
CpG dinucleotides surrounding the transcription start 
site of  LGALS1 promoter were frequently methylated 
in non-tumor liver, whereas these sequences were hypo-
methylated in HCC tissues. Interestingly, using a mobility 
shift assay with nuclear extracts from three HCC cell lines 
(HLF, HuH7, and HepG2) as well as human embryonic 
primary liver (PL) cells, the authors showed specific inter-
action of  a methylation-sensitive factor to the upstream 
and downstream regulatory elements which appear to 
be essential for the activation of  the LGALS1 gene in 
HCC cells[80]. Northern blot analysis demonstrated that 
galectin-1 mRNA was up-regulated in primary HCC in 
comparison to adjacent non-tumor liver tissues and hu-
man normal liver tissues. In fact, galectin-1 mRNA level 
was higher in the HuH-7 and HLF HCC cell lines as 
compared to HepG2 and PL cells[80]. 
HCC primary tumorNormal liver
HBV/HCV infection
Chronic inflammation
Alcoholic abuse
Aflatoxin exposure
Genetic/epigenetic 
microenvironment changes
Adhesion to ECM
Space of disse
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Tumor growth
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Figure 1  Galectins in hepatocellular carcinoma. In normal liver, galectin (Gal)-8 and galectin-9 are expressed in hepatocytes whereas galectin-1, galectin-3 and 
galectin-4 are not detectable. This expression pattern is altered in hepatocellular carcinoma (HCC) as galectin-1, galectin-3 and galectin-4 are up-regulated, whereas 
galectin-8 and galectin-9 are down-regulated in transformed hepatocytes. This aberrant expression favors tumor growth and hepatocyte adhesion to extracellular ma-
trix (ECM), migration, adhesion to the endothelium, transendothelial invasion and metastasis. Galectin-3, normally absent in sinusoid endothelial cells, is up-regulated 
in tumor capillary endothelial cells, probably promoting angiogenesis. Increased expression of galectin-1 and lack of galectin-9 expression also contribute to tumor-
immune escape. HBV: Hepatitis B virus; HCV: Hepatitis C virus.
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in the delicate stroma tissue surrounding tumor hepa-
tocytes of  HCC tumors. The authors hypothesized that 
neoplastic hepatocytes secrete galectin-1 which is then 
accumulated in the stroma surrounding HCC (Figure 1 
and Table 1).
The correlation between increased expression of  
galectin-1 in HCC and the presence of  metastasis was 
validated by in vitro functional studies. Expression of  
LGALS1 gene and secretion of  galectin-1 protein were 
substantially up-regulated in JHH-6 (undifferentiated 
cells) and HuH-7 (differentiated cells). Notably, galectin-1 
over-expression increased the migratory and invasive ca-
pacities of  HuH-7 cells, and both processes were mediat-
ed by the stimulation of  the Sky receptor tyrosine kinase 
(RTK) phosphorylation. Thus, similar to breast cancer[68], 
neuroblastoma[83], oral squamous cell carcinoma and lung 
adenocarcinoma[84], galectin-1 expression correlates with 
HCC tumor aggressiveness (Figure 1 and Table 1).
Under this scenario, we have focused our attention 
on the role of  galectin-1 and its contribution to HCC 
development. In this regard, we examined the involve-
ment of  this galectin in HepG2 HCC cell adhesion 
and tumor growth[85]. We found that galectin-1 acts as a 
glycan-dependent matricellular modulator of  HepG2 cell 
adhesion. We observed that galectin-1 favored cell adhe-
sion to laminin, a polylactosamine-enriched glycoprotein 
and a major component of  the ECM and basement 
membranes. Moreover, we demonstrated that the pro-
adhesive effects of  galectin-1 are specifically mediated by 
α1, α2, α3, αv, and β1 integrins and involve PI3K and/or 
ERK1/2 signaling pathways. Besides, galectin-1 over-
expressing HepG2 cells showed an increased secretion of  
this lectin to the extracellular compartment and remark-
ably, we also found that exogenously added recombinant 
galectin-1 was internalized by HepG2 cells[85]. Hence, in 
accordance with Spano et al[81], galectin-1 secreted from 
HCC cells might exert its biological functions either by 
engaging cell surface receptors and transmitting signals in-
side the cell or through receptor-mediated internalization 
and endocytosis. However, because intracellular functions 
have also been described for this protein[42] a cell surface-
independent mechanism responsible for galectin-1 func-
tions cannot be excluded. We also found that galectin-1 
up-regulation in the tumor microenvironment favored 
HCC growth in vivo and promoted a considerable increase 
in tumor metastasis. This effect was evident in draining-
tumor lymph nodes of  mice injected with galectin-1 
over-expressing HepG2 cells[85]. Collectively, these results 
suggested the involvement of  galectin-1 in neoplastic and 
inflammatory processes of  the liver (Figure 1 and Table 1).
Compelling evidence indicates that high expression of  
galectin-1 predicts poor patient outcome in a variety of  
tumors. However, the prognostic value of  this endogenous 
lectin in HCC patients remained elusive for many years. 
Recently, Wu et al[82] reported that elevated galectin-1 ex-
pression in HCC is significantly associated with tumor ag-
gressiveness (vascular invasion, incomplete encapsulation, 
poor differentiation, and large tumor size) and enhanced 
  Galectin member Expression Function and/or effect Model Ref.
  Galectin-1 Up-regulated (mRNA and protein) in 
HCC, secreted by tumor hepatocytes and 
accumulated in stroma surrounding HCC
Correlates with tumor aggressiveness, 
metastases and enhanced risk of post-
operative recurrence
Human HCC tissues [79-82]
Favors HCC cell adhesion to ECM, cell 
migration and invasion
Human HCC cell lines [81,85]
Increases tumor growth and metastasis in 
draining-tumor lymph nodes
Nude mice injected with galectin-1 
over-expressing HepG2 cells
[85]
Possible role in the suppression of 
antitumor immune responses
Human HCC tissues [82]
  Galectin-3 Up-regulated (mRNA and protein) in 
HCC. Transactivation of murine LGALS3 
promoter can occur by HBV-X protein.
Human HCC tissues and cell lines [79,124,125]
High nuclear expression Correlates with histological differentiation 
and vascular invasion
Human HCC tissues [126]
Up-regulated in HCC-associated capillary 
endothelial cells
Probably promotes angiogenesis Tumor-associated endothelial cells 
isolated from rats
[128]
  Galectin-4 Higher expression in HCC than normal 
tissues
Human HCC tissues and cell lines [154]
  Galectin-8 Diminished expression in hepatoblastoma 
and hepatocarcinoma
Human HCC tissues [159]
  Galectin-9 Downregulated in HCC Galectin-9 suppression promotes cell 
proliferation and adhesion to ECM, tumor 
cell-endothelial cell adhesion and trans-
endothelial invasion of HepG2 cells.
Human cell lines [181]
Downregulation of galectin-9 represents a 
risk factor for patient survival, correlates 
with tumor histopathological grade, 
vascular invasion and metastasis
Human HCC tissues [181]
Table 1  Involvement of galectins in the pathogenesis of hepatocellular carcinoma
HCC: Hepatocellular carcinoma; ECM: Extracellular matrix; HBV: Hepatitis B virus.
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risk of  post-operative recurrence. Additionally, galectin-1 
expression in HCC was also associated with early tumor re-
currence (≤ 24 mo) and dissemination of  primary tumor 
cells. Furthermore, a positive correlation was observed be-
tween galectin-1 expression and tumor-infiltrating FoxP3+ 
regulatory T cells (Tregs) in HCC samples from a large, 
random HCC cohort. In line with this evidence, it has been 
demonstrated that galectin-1 is a key regulator of  murine 
CD4+CD25+ regulatory Tregs[86] which play an essential 
role in suppression of  anticancer immunity[87]. Taken this 
information into account it is possible to speculate that 
interaction between galectin-1 and Treg cells might play a 
role in the suppression of  antitumor immune responses 
against HCC (Figure 1 and Table 1). 
The immunomodulatory activities of  galectin-1 in 
the liver were also investigated in a model of  hepatitis in-
duced by injection of  concanavalin A (Con A) into mice, 
which leads to a dose-dependent injury in the liver[88]. 
T-cell activation is a crucial event in this model as shown 
by resistance to this inflammatory disease of  mice lack-
ing T and B lymphocytes. Furthermore, pretreatment 
with anti-interferon γ (IFN-γ) or anti-tumor necrosis fac-
tor (TNF) monoclonal antibodies conferred protection 
against Con A-induced liver injury, indicating that Th1-
  Galectin member Experimental model Role Effects Ref.
  Galectin-1 Hepatitis induced by injection of Con 
A
Protective Prevents both liver injury and T-helper cell liver infiltration, 
induces apoptosis of Con A-activated T cells, suppresses 
plasma levels of TNF and IFN-γ
[89]
Inflammation-induced chronic 
cholestatic hepatitis at an early age, 
and HCC at later age (Mdr2-KO mice)
Protective Galectin-1 is up-regulated in Mdr2-KO/B6 strain at early age [91]
Galectin-1-KO mice in the context of 
Con A-induced autoimmune hepatitis
Protective Con A up-regulates galectin-1 in galectin-1-KO/B6 and Mdr2-
KO/FVB strains. Endogenous galectin-1 selectively protects 
liver in the B6, but not in the FVB genetic background. It 
probably determines strain-specific differences in the course of 
chronic hepatitis and HCC development in the Mdr2-KO model
[91]
  Galectin-3 NASH model Galectin-3-KO mice Protective Develops NAFLD/NASH spontaneously with aging [140,141]
CDAA diet-induced 
NAFLD/NASH in 
galectin-3-KO mice
Protective Galectin-3 deficiency causes more severe hepatic injury 
and alterations in the expression of genes associated with 
carcinogenesis and lipid metabolism
[142]
Atherogenic diet-
induced NASH in 
galectin-3-KO mice
Promotes disease 
severity
Attenuates NASH: inhibits HSC-driven fibrosis, reduces 
inflammatory-cell infiltration and hepatocyte apoptosis, acts as 
a major scavenger receptor involved in ALE/AGE uptake by 
the liver
[143]
Human liver tissues Protective Negative expression of galectin-3 in normal hepatocytes, 
strong staining for galectin-3 in hepatocytes from patients with 
steatosis hepatitis, hepatitis, cholestasis and cirrhosis
[145]
Acute liver failure induced by APAP- 
hepatotoxicity in galectin-3-KO mice
Perpetuates liver 
injury
In wild type mice, galectin-3 is up-regulated in liver infiltrating 
macrophages. In galectin-3 deficient mice the pro-inflammatory 
M1-type macrophages subpopulation, the classical macrophage 
activation markers iNOS, TNF and IL-12 and pro-inflammatory 
chemokines are reduced
[147,148]
Hepatitis induced by injection of Con 
A in galectin-3-KO mice
Pro-inflammatory Galectin-3 deficiency reduces the number of T lymphocytes, B 
lymphocytes, dendritic cells, NK and NKT cells and enhances 
apoptosis of mononuclear cells
[149]
Con A-induced liver injury in wild 
type mice pretreated with a selective 
inhibitor of galectin-3 (TD139)
Pro-inflammatory TD139 attenuates liver injury, reduces the number of CD4+ and 
CD8+ T cells, favors the influx of IL-10-producing CD4+ T cells 
in the liver, decreases serum levels of IFN-γ, IL-17 and IL-4
[149]
  Galectin-9 Blockade of the TIM-3/galectin-9 
pathway using an anti-TIM-3 or anti-
galectin-9 mAb in a context of liver 
IRI
Protective Blockade of the TIM-3/galectin-9 pathway increases 
hepatocellular damage, local neutrophil infiltration, T cell and 
macrophage accumulation and liver cell apoptosis. Increases 
IFN-γ production by Con A-stimulated spleen T cells and 
augmented TNF and IL-6 production  by Con A-stimulated 
macrophages/T cells
[190]
Single injection of galectin-9 in the 
murine model of liver injury induced 
by Con A
Protective Eliminates activated CD4+ effector T cells, prevents the 
synthesis and/or release of proinflammatory cytokine
[191]
Mouse model of diet-induced NAFLD 
treated with galectin-9
Limits the 
inflammatory 
response
Induces apoptosis of NKT cells, also interacts with TIM-3-
expressing Kupffer cells to induce secretion of IL-15, thus 
promoting NKT cell proliferation
[195]
Table 2  Galectins in inflammation-associated liver injury
ALE/AGE: Advanced lipoxidation and glycation end products; APAP: Acetaminophen; CDAA: Choline-deficient L-amino-acid; Con A: Concanavalin A; 
HSC: Hepatic stellate cells; IFN-γ: Interferon γ; IL: Interleukin; iNOS: Inducible isoform nitric oxide synthase; IRI: Ischemia and reperfusion injury; NAFLD: 
Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; NK: Natural killer; NKT: NK T cells; TIM-3: T-cell immunoglobulin mucin domain 3; 
TNF: Tumor necrosis factor; HCC: Hepatocellular carcinoma; KO: Knockout.
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dependent cytokines are involved in this inflammatory 
disease. Interestingly, it has been demonstrated that galec-
tin-1 exerts a protective role on Con A-induced autoim-
mune hepatitis in mice (Table 2)[89].
 Recently, the protective role of  galectin-1 in the liver 
inflammatory response was investigated using the Mdr2-
knockout (Mdr2-KO) mice as a model of  inflammation-
induced chronic cholestatic hepatitis at an early age, and 
HCC at a later age, which together mimic the evolution 
of  human disease[90]. Potikha et al[91] demonstrated that 
HCC development was retarded in Mdr2-KO/B6 strain 
compared to Mdr2-KO/FVB mice. Interestingly, up-
regulation of  galectin-1 transcript in the liver of  Mdr2-
KO/B6 mice was observed[91]. To highlight the relevance 
of  the endogenous protein galectin-1-KO/B6 mice were 
used in the context of  Con A-induced autoimmune 
hepatitis. The results demonstrated that endogenous ga-
lectin-1 selectively protects against Con A-induced liver 
injury in B6 mice (Table 2)[91]. 
Collectively, these data indicated that galectin-1 has an 
important role in HCC tumor growth, aggressiveness and 
metastasis (Figure 1 and Table 1). Moreover, they suggest 
that galectin-1 may act as a protective anti-inflammatory 
agent at early stages of  the chronic liver pathology dur-
ing inflammation-induced hepatocarcinogenesis, but as a 
pro-tumorigenic agent at late stages of  the disease.
Galectin-1 in fibrosis-related liver pathologies
Hepatic fibrosis is the physiological result of  the wound-
healing response of  the liver to repeated injury. This 
process is associated with an inflammatory response 
and a limited deposition of  ECM. If  the hepatic injury 
persists (e.g., chronic viral hepatitis), and eventually the 
liver regeneration fails, hepatocytes are substituted with 
abundant ECM, including fibrillar collagen[92]. Kristense 
et al[93] conducted a proteome analysis on cellular and 
secreted proteins of  normal (quiescent) and activated rat 
hepatic stellate cells (HSCs), the main ECM-producing 
liver cells. These researchers found that galectin-1 was 
up-regulated in both in vivo and in vitro activated HSCs, 
and in fibrotic liver tissues[93]. When the biological role of  
galectin-1 was investigated in HSCs, it was found that this 
lectin stimulated the proliferation rate and migratory ac-
tivity of  cultured HSCs through carbohydrate-dependent 
mechanisms (Table 3)[94]. These data clearly indicated that 
galectin-1 has an important role in the development of  
liver fibrosis.
By immunohistochemistry, galectin-1 expression was 
also assessed in the intrahepatic biliary tree. The intrahe-
patic biliary epithelial cells or cholangiocytes are involved 
in modifying the bile of  canalicular origin. Cholangiocar-
cinoma occurs frequently associated with inflammation 
and fibrosis of  bile ducts, and is caused by multiple fac-
tors including autoimmune, bacterial, congenital, drug, 
or viral agents[95]. In normal livers, Shimonishi et al[96] 
observed that intrahepatic bile ducts and hepatocytes did 
not express galectin-1. Remarkably, 73 % of  the intrahe-
patic cholangiocarcinoma (ICC) samples analyzed were 
positive for galectin-1[96]. Expression of  this lectin signifi-
cantly correlated with histologic dedifferentiation of  ICC, 
  Galectin Member Expression Function and/or effect Model Ref.
  Galectin-1 Over-expressed in 
activated HSCs
Induces proliferation of HSCs via ERK 1/2 through 
CRD domain
HSCs activated in vitro (cultured on 
plastic for several days) and in vivo 
(isolated form rats treated with CCl4 or 
with bile duct ligation)
[93,94]
Positive in ICC cells, 
intracellular expression 
and secretion
Correlates with histologic dedifferentiation, vascular 
invasion, and lymph node metastasis
ICC tissue samples, CCKS1 
cholangiocarcinoma cell line
[96]
  Galectin-3 Over-expressed in 
activated HSCs
Induces proliferation via ERK 1/2 involving PKA and 
PKC pathways
Dependent on CRD domain
HSCs activated in vitro  (cultured on 
plastic for several days) and in vivo 
(isolated form rats treated with bile 
duct ligation)
[94]
Intracellular Gal3 is required for activation 
of HSCs via TGF-β
 HSCs activated in vivo (isolated form 
rats treated with CCl4)
[132]
Extracellular Gal3 required for activation of HSCs. 
Integrin and CRD dependent effect
HSCs activated in vivo (isolated from 
rats with bile duct ligation)
[134]
NFκβ induces expression and secretion of Gal3 in 
activated HSCs
Up-regulated in 
injured/cirrhotic 
hepatocytes
Poor liver function Human fibrotic liver samples and 
extracts from rats treated with CCl4
[124,133,136]
Related to the preneoplastic and early neoplastic 
stages of ICC
ICC tissue samples [96,137]
Positive in ICC cells Intracellular expression is associated with
anti-apoptotic activity and resistance to 
chemotherapeutic agents
ICC cell lines [138]
Table 3  Galectins in fibrosis-related liver pathologies
HSC: Hepatic stellate cells; CRD: Carbohydrate recognition domain; ERK: Extracellular signal-regulated kinase; ICC: Intrahepatic cholangiocarcinoma; 
PKA: Protein kinase A; PKC: Protein kinase C.
Bacigalupo ML et al . Galectins in liver pathology
8838 December 21, 2013|Volume 19|Issue 47|WJG|www.wjgnet.com
vascular invasion, and lymph node metastasis of  ICC[96]. 
These results suggest that galectin-1 over-expression in 
ICC cells is associated with neoplastic progression and 
tumor cell proliferation (Table 3). 
These results highlight an important role of  galectin-1 
in chronically injured liver and its involvement in inflam-
mation and fibrosis of  bile ducts, thus providing the basis 
for the development of  effective therapies based on the 
modulation of  galectin-1-glycan interactions.
GALECTIN-3
Galectin-3 is the unique ‘‘chimera-type’’ galectin contain-
ing three structurally distinct domains, an atypical N-ter-
minal domain that includes a serine phosphorylation site, 
important for the regulation of  intracellular signaling, a 
collagen-like sequence sensitive to proteolysis by MMP-2 
and MMP-9 matrix metalloproteinases and a C-terminus 
containing one carbohydrate-recognition domain (CRD) 
containing an Asp-Trp-Gly-Arg motif. This sequence mo-
tif  is also present in members of  the B-cell lymphoma 2 
(Bcl-2) family of  apoptosis regulators, and is responsible 
for the antiapoptotic activity of  galectin-3[97]. In solution, 
galectin-3 largely occurs as a monomer[98]. Although in the 
absence of  its binding partners it can form homodimers 
by self-association through its CRDs[99], in the presence 
of  carbohydrate ligands, galectin-3 can polymerize up to 
pentamers through its N-terminal domain[99,100].
Galectin-3 is mainly localized at the cytoplasmic com-
partment, but it is also present within the nucleus, in the 
cell surface or in the extracellular space[29,101]. Transloca-
tion of  this lectin from the cytoplasm to the nucleus is 
mediated by its N-terminal domain[102], whilst transloca-
tion from nucleus to the cytoplasm involves a nuclear 
export sequence located within its CRD[103] and occurs 
through nucleoporin NP98[104]. Notably, the N-terminal 
domain is also required for the secretion of  the lectin to 
the extracellular milieu[105]. 
Galectin-3 has multiple and complex functions. In the 
cytoplasm, galectin-3 can bind to Bcl-2 and inhibit cel-
lular apoptosis[97]. Also, it can interact with the activated 
K-Ras (K-Ras-GTP)[106,107] and affect Ras-mediated Akt 
signaling[108,109]. On the other hand, nuclear galectin-3 acts 
as a pre-mRNA splicing factor and is involved in spliceo-
some assembly[110] by forming protein complexes with 
Gemin4[111]. In the nucleus, Galectin-3 can also regulate 
gene transcription by enhancing transcription factor as-
sociation with Spi1 and CRE elements in gene promoter 
sequences[29]. In addition, β-catenin, a molecule involved 
in Wnt signaling pathway, was also identified as a novel 
binding partner of  galectin-3 in the nucleus[112]. 
On the other hand, extracellular galectin-3 mediates 
cell adhesion and activation and also acts as a chemoat-
tractant for certain cell types[29]. It often forms multimers 
and thus, it cross-links cell surface ligands forming lattice-
like structures which trigger cell signaling[29]. Galectin-3 
has been shown to bind glycosylated components of  the 
extracellular matrix, and cell-surface adhesion molecules 
like integrins[43]. Pro-apoptotic activity of  extracellular ga-
lectin-3 was observed in several cell types, such as human 
T leukemia cell lines, human peripheral blood mono-
nuclear cells, and activated mouse T cells[113].
Galectin-3 is widely expressed in human tissues, in-
cluding immune cells, epithelial cells and sensory neurons 
(reviewed by[29]). This lectin regulates immune cell activi-
ties and contributes to immunosuppression as it induces 
monocyte and T-cell apoptosis, suppresses IL-15 produc-
tion and inhibits B-cell differentiation[114,115]. In general, 
galectin-3 is a powerful pro-inflammatory signal as dem-
onstrated by both in vitro and in vivo assays[29,116]. Extracel-
lular galectin-3 has been demonstrated to activate and 
modulate the viability of  immune and inflammatory cells, 
although the effects of  Galectin-3 in T-cell survival are 
dependent on whether the protein is produced endog-
enously (anti-apoptotic) or is secreted to the extracellular 
medium (pro-apoptotic)[114,116].
Expression of  galectin-3 and its intracellular distribu-
tion are frequently altered in cancer and pre-cancerous 
conditions[26], and it is evident that this lectin plays 
multiple roles in cancer pathogenesis, proliferation and 
spreading of  metastasis[29,62,117]. Pre-clinical and clinical 
data indicate that expression of  galectin-3 is associated 
with the carcinogenesis and malignant potential in mela-
noma, head and neck, thyroid, gastric, colon, uterine, and 
renal cancers[118]. In fact, galectin-3 contributes to tumori-
genesis and tumor progression through several different 
mechanisms, including promotion of  oncogenesis, angio-
genesis, adhesion, invasion and metastasis[101,115]. 
The mechanisms of  regulation of  galectin-3 expres-
sion are still poorly understood. The promoter region of  
the human galectin-3 gene (LGALS3) contains several 
regulatory elements for activation by the SP1, AP-1, 
CREB, and NF-κB transcription factors[119]. In this re-
gard, c-Jun, CREB, and NF-κB have been implicated in 
activation of  the LGALS3 gene[29,49]. Galectin-3 expres-
sion is also regulated by methylation of  CpG islands in 
the promoter region. It has been demonstrated that de-
methylation of LGALS3 promoter induces expression of  
galectin-3 in thyroid carcinoma[120,121]. Recently, Margadant 
et al[122] demonstrated that, in cells from epithelial origin, 
integrin β1 specifically triggers transcriptional activation 
of  galectin-3 through a mechanism that involves demeth-
ylation of  the LGALS3 promoter. Further, it has been 
shown that the cell-surface glycoprotein MUC1 controls 
galectin-3 expression in an epigenetic manner in cancer 
cells, through a miRNA-dependent mechanism[123].
Galectin-3 in HCC
Hsu and colleagues demonstrated using immunohisto-
chemistry and immunoblot analysis, that normal hepa-
tocytes do not express galectin-3; however this galectin 
is prominently up-regulated in HCC tissues and in HCC 
cell lines[124]. Increased expression of  galectin-3 in HCC 
was independent of  whether the patients were previously 
exposed to hepatitis B virus (HBV). However, galectin-3 
expression in HCC was positively influenced by HBV 
infection through a mechanism that included transac-
tivation of  the murine LGALS3 gene promoter[124]. 
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Accordingly, using cDNA microarray and gene expres-
sion profiling, Chung et al[79] reported the up-regulation 
of  Galectin-3 in HCC human tissues with respect to 
their normal counterparts. Moreover, by analyzing gene 
expression patterns, Luo et al[125] also reported the over-
expression of  galectin-3 gene in HCC tissues respect to 
normal liver and adjacent non-tumoral tissues. 
Interestingly, expression of  galectin-3 correlated with 
histological differentiation and vascular invasion in HCC 
patients[126]. In particular, higher expression rate of  nucle-
ar galectin-3 denoted worse prognosis in this pathology 
and serum galectin-3 levels were found to be increased in 
HCC patients compared to those suffering chronic liver 
disease[126]. These results highlighted a central role for ga-
lectin-3 in HCC development and progression (Figure 1 
and Table 1). 
HCC is a hypervascular tumor in which angiogenesis 
plays a critical role. Tumor-associated capillary endothelial 
cells (TECs) in HCC are known to originate from liver 
sinusoid endothelial cells (SECs), which then undergo a 
capillarization process to become morphologically and 
functionally different TECs[127]. Using two-dimensional 
gel electrophoresis coupled to mass spectrometry, Jia et 
al[128] observed that galectin-3 is up-regulated in TECs, 
respect to SECs. This result validated by immunoblot and 
immunohistochemistry, demonstrated that galectin-3 is 
generally absent in liver SECs, but is significantly up-reg-
ulated in HCC TECs (Table 1)[128]. Further investigation 
is required to reveal whether galectin-3 produced in HCC 
TECs could influence HCC angiogenesis.
EGFR family is an important mediator of  cancer 
cell transformation, proliferation, maintenance, and sur-
vival[129]. Paradoxically, high concentrations of  epidermal 
growth factor (EGF) initiates different signaling cascades 
and mainly induces apoptosis of  tumor cells expressing 
high levels of  EGF receptor[130]. Recently, the role of  ga-
lectin-3 in EGF-induced apoptosis on HepG2 cells was 
investigated[131]. Indeed, high concentrations of  EGF in-
hibited proliferation and induced apoptosis of  these cells, 
concomitantly with a reduced expression of  galectin-3 
at both mRNA and protein levels[131]. Also, high levels 
of  EGF down-regulated the expression of  cytoplasmic 
galectin-3. Remarkably, the reduced expression of  galec-
tin-3 in EGF-treated cells was associated with reduced 
phosphorylation of  Akt and ERK. Moreover, over-
expression of  galectin-3 in HepG2 cells blocked EGF-in-
duced growth inhibition and apoptosis[131]. Thus, cellular 
proliferation and/or apoptosis induced by EGF signaling 
pathway in HCC cells might rely on the expression levels 
of  galectin-3. 
Collectively, these results demonstrate that galectin-3 
over-expression correlates with HCC progression (Figure 
1 and Table 1) and suggest that this lectin could serve as 
a novel biomarker and therapeutic target in HCC.
Galectin-3 in fibrosis-related liver pathologies
Expression of  galectin-3 is increased in liver fibrosis re-
gardless of  the initiating agent or disease process[94,132]. 
In vitro experiments and different experimental models 
of  liver injury and fibrosis demonstrated that galectin-3 
stimulated the proliferation rate of  cultured activated 
HSCs and is also involved in myofibroblast activation, 
identifying galectin-3 as a potential therapeutic target in 
the treatment of  liver fibrosis (Table 3)[94,132-134].
Liver fibrosis leads to progressive liver insufficiency, 
portal hypertension and ultimately to cirrhosis and/or 
HCC[135]. In patients with liver cirrhosis galectin-3 is 
not extracted by the liver[136], and also, its expression is 
induced in hepatocytes of  cirrhotic liver[124,136]. Further-
more, galectin-3 was negatively associated with liver func-
tion in patients with alcoholic liver cirrhosis, an effect 
which might be partly explained by the impaired hepatic 
removal and/or by higher hepatic synthesis of  galectin-3 
(Table 3)[136].
As mentioned before, cholangiocarcinoma frequently 
occurs in a context of  inflammation and fibrosis of  bile 
ducts. Shimonishi et al[96] examined galectin-3 expression 
pattern in intrahepatic cholangiocarcinoma (ICC), and 
found that 93% of  the ICC samples analyzed were posi-
tive for this lectin. The expression was more intense in 
well-differentiated ICC, and was significantly decreased 
in dedifferentiated areas or poorly differentiated ICCs, 
indicating that galectin-3 expression is rather related to 
the preneoplastic and early neoplastic stages of  ICC, and 
tends to disappear at later stages of  ICC (Table 3)[96,137]. 
Also, it has been demonstrated that galectin-3 played 
a role in apoptosis and response to chemotherapy in 
cholangiocarcinoma cell lines (Table 3)[138]. These results 
highlight the possibility of  targeting galectin-3 as an alter-
native therapeutic approach in cholangiocarcinoma.
Galectin-3 in inflammation-associated liver injury
Non-alcoholic fatty liver disease (NAFLD) is increasingly 
recognized as a condition in which excess fat accumulates 
in hepatocytes. NASH, a severe form of  NAFLD in 
which inflammation and fibrosis of  the liver take place, 
may eventually progress to end-stage liver disease and ul-
timately, to HCC[139]. Controversial results have been pub-
lished on the effect of  galectin-3 deficiency in models of  
hepatic steatosis/inflammation, with studies indicating ei-
ther protection or increased disease severity in galectin-3 
knock-out (KO) mice (Table 2)[140-143]. On one hand, it has 
been demonstrated that in choline-deficient L-amino-acid 
(CDAA) diet-induced NAFLD/NASH hepatic injury 
was more severe in galectin-3 KO mice, as compared to 
wild type mice[142]. 
On the other hand, Iacobini et al[143] reported a com-
plete prevention or marked attenuation of  NASH in-
duced by an atherogenic diet in galectin-3 KO mice. In 
these animals, the earlier steps of  NASH, e.g., steatosis, 
hepatocyte injury, and inflammation, were dramatically 
influenced[143]. Further research is needed to elucidate the 
protective or promoting roles of  galectin-3 in liver ste-
atosis and inflammation.
Excess fatty acid oxidation and generation of  reactive 
carbonyls with formation of  advanced lipoxidation and 
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glycation end products (ALEs and AGEs, respectively) 
are involved in NASH. Several AGE-binding proteins 
have been identified including galectin-3, which has been 
widely recognized as an AGE receptor (AGE-R3)[144]. 
Butscheid et al[145] explored the expression of  galectin-3 
and RAGE, a member of  the immunoglobulin super-
family which also serves as a receptor for AGEs, in 
specific cell types and histological structures of  human 
liver biopsy specimens from patients with varying de-
grees of  hepatic impairment (steatosis hepatitis, hepati-
tis, cholestasis and cirrhosis). They observed that when 
liver function is impaired and AGE levels rise, over-
expression of  galectin-3 appears to contribute to tissue 
protection (Table 2)[145]. 
Acetaminophen (APAP)-induced hepatotoxicity is a 
major cause of  acute liver failure[146]. Evidence suggests 
that activated macrophages contribute to the pathogenic 
response to APAP and, two major phenotypically distinct 
subpopulations have been identified: classically activated 
(M1-type) macrophages which show pro-inflammatory 
function and alternatively activated (M2) macrophages 
which often display anti-inflammatory wound repair 
activities[147]. It appears that the outcome of  tissue in-
jury depends on which macrophage subpopulation 
predominates. In wild type mice, galectin-3 is markedly 
up-regulated in macrophages infiltrating the liver 48-72 
h after APAP administration[147]. Interestingly, loss of  ga-
lectin-3 resulted in reduced hepatotoxicity and decreased 
expression of  proinflammatory mediators[148]. Taken 
together, the data suggest that galectin-3 plays a key role 
in promoting late pro-inflammatory responses, classical 
macrophage activation and perpetuating injury in the liver 
following APAP intoxication (Table 2). 
Supporting these findings, Volarevic et al[149] showed 
that galectin-3 deficiency leads to a marked attenuation 
of  Con A-induced hepatitis. This effect was associated 
with a decreased number of  effector cells in the liver. 
Moreover, pretreatment of  wild type mice with a selec-
tive inhibitor of  galectin-3 (TD139) attenuated Con 
A-induced liver injury and reduced the number of  CD4+ 
and CD8+ T cells (Table 2)[149]. Hence, galectin-3 plays 
an important pro-inflammatory role in Con-A-induced 
hepatitis and may function as a potential target for thera-
peutic intervention in acute liver diseases.
GALECTIN-4 
Galectin-4 is a “tandem-repeat” galectin, which possesses 
two CRDs and is primarily expressed in epithelial cells 
along the gastrointestinal tract[150]. Recently, this lectin 
has been reported as a major component of  lipid rafts 
in brush border membranes of  small intestinal epithelial 
cells[151]. In a human colon adenocarcinoma cell line, ga-
lectin-4 has been proposed to play an important role in 
the apical delivery of  proteins[152]. 
Galectin-4 expression is altered in human malig-
nancies[46,62,150]. Although controversial data has been 
published, it is apparent that galectin-4 is significantly 
down-regulated in colon adenocarcinoma. In fact, it has 
been recently demonstrated that galectin-4 functions 
as a tumor suppressor in this type of  malignancy[153]. In 
contrast, galectin-4 expression is higher in HCC[154] and 
gastric cancer cell[155], as compared to their correspond-
ing normal tissues, suggesting a context-dependent role 
of  galectin-4 in tumor development and progression. 
Kondoh et al[154] identified several cDNAs that were dif-
ferentially expressed in surgically resected human HCC as 
compared to non-tumor liver and normal liver tissues[154]. 
Non-tumor liver tissues were obtained from patients that 
suffered cirrhosis associated with HCV infection and, 
from patients suffering liver cirrhosis but in the absence 
of  HCV or HBV infection. Normal liver tissues that 
were used as controls were obtained from patients who 
died of  pancreatic carcinoma and subarachnoid bleeding. 
Interestingly, one of  the genes differentially expressed 
was the galectin-4 gene (LGALS4). Northern blot analy-
sis revealed that galectin-4 mRNA was more abundant in 
HCCs than in adjacent non-tumor liver tissues or normal 
liver tissues from non-HCC patients[154]. When HCC cell 
lines were analyzed (HuH-7 and HepG2 cells), the levels 
of  galectin-4 mRNA were undetectable or low in rapidly 
growing cells. However, the levels of  this lectin increased 
considerably in HuH-7 cells growing at a higher cell 
density, although the expression of  galectin-4 did not 
increase in HepG2 cells. Furthermore, the expression 
of  galectin-4 mRNA was also induced in HuH-7 cells 
cultured with low concentration serum (0.1%)[154]. Thus, 
although the precise roles of  galectin-4 in HCC remained 
to be elucidated, these results show a possible associa-
tion between galectin-4 expression and liver malignancy. 
Functional studies will provide insight to further under-
stand the role of  galectin-4 in HCC biology.
GALECTIN-8
Galectin-8 is another member of  the “tandem-repeat”-
type family of  galectins, which possesses two CRDs and 
thus, behaves as a bivalent molecule. The galectin-8 gene 
(LGALS8) encodes numerous mRNAs (most likely sev-
en) generated through alternative splicing, mostly in in-
tron Ⅷ[156]. Because the N-terminal domain of  galectin-8 
intrinsically dimerizes[157], cleavage of  the linker region 
between galectin-8N and galectin-8C may allow the pos-
sibility to dissect potential signaling pathways initiated by 
each separate domain[46].
This lectin has been initially cloned from a rat liver 
cDNA library[158]. Using Northern analysis it was estab-
lished that galectin-8 mRNA is highly expressed in lungs 
and, to a lesser extent in the liver, kidneys, spleen, hind-
limb and cardiac muscles in the rat[158]. The role of  galec-
tin-8 has been mostly investigated in relation to tumor 
malignancy[62,156] in a variety of  different tumors from dif-
ferent origin[62,159]. Immunohistochemical studies revealed 
that galectin-8 expression is increased in cancerous versus 
normal tissues in the lung, bladder, kidney, prostate and 
stomach. However, in the liver and also in large intestine, 
pancreas, larynx and skin, immunohistochemical analysis 
revealed decreased expression of  this lectin in cancerous 
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versus normal tissues, suggesting tissue-specific regula-
tion of  galectin-8 expression in cancer[159]. In normal and 
cirrhotic livers, the staining intensities of  galectin-8-
positive cells appeared to be moderate to strong. On the 
contrary, in hepatoblastomas and hepatocarcinomas the 
staining intensity of  positive cells was weak to moderate. 
Collectively, these experiments revealed tissue-specific 
regulation of  galectin-8 expression upon malignant trans-
formation of  various tissue types of  epithelial origin. 
Further investigation is necessary to further delineate the 
functional roles of  galectin-8 in liver carcinogenesis and 
to determine if  galectin-8 downregulation is associated 
with poor prognosis of  HCC.
GALECTIN-9
Galectin-9 is a “tandem-repeat” galectin originally iso-
lated from mouse embryonic kidney cells[160]. Galectin-9 
consists of  two different CRDs joined by a flexible pep-
tide linker, with 39% amino acid sequence homology. 
The C-terminal CRD and the N-terminal CRD share 
high affinity for both branched N-glycans and repeated 
oligo-lactosamines. Further, the N-CRD exhibits striking 
affinity for the Forssman pentasaccharide and polymer-
ized N-acetyllactosamine[161,162]. Alternative splicing leads 
to the formation of  three splice variants that vary only in 
the length of  the peptide linker. The 35.9 kDa medium-
sized isoform (galectin-9M) corresponds to authentic 
galectin-9 whereas the long and small-sized isoforms 
(galectin-9L and S) have a 32-amino acid insertion and 
a 12-amino acid deletion, respectively in the linker pep-
tide[36]. The length of  this region influences the rotational 
flexibility of  the two CRDs in the space, impacting on 
galectin-9 valency[163].
Human galectin-9 was first identified as a tumor an-
tigen in Hodgkin’s lymphoma, a condition characterized 
by abundant blood and tissue eosinophilia[164] and it is 
widely distributed within the immune system. This galec-
tin is known to play a variety of  cellular roles, including 
modulation of  cell differentiation, adhesion, aggrega-
tion, and cell death[165]. Through modulation of  cell sig-
naling, this lectin can regulate multiple physiological and 
pathological processes such as immunity, inflammation, 
and cancer. 
Galectin-9 has been identified as a ligand for the T-cell 
immunoglobulin mucin domain 3 (TIM-3), a membrane 
glycoprotein expressed on the surface of  Th1, Th17 and 
citotoxic T cells, as well as in natural killer (NK) cells, 
monocytes, dendritic cells, macrophages and mast cells 
(reviewed by[166]). The galectin-9/TIM-3 pathway plays a 
dual role in immunity. On one hand, it favors a pro-in-
flammatory response, induces maturation of  monocyte-
derived dendritic cells, and through this process, enhanc-
es Th1-type immune responses[167]. On the other hand, 
galectin-9 contributes to apoptosis of  thymocytes and 
peripheral T cells, implicating a dual role of  the Galec-
tin-9/TIM-3 axis in both T-cell maturation and negative 
regulation of  T-cell-mediated immune reactions[168,169]. 
Blocking or activation of  the Galectin-9/TIM-3 signaling 
pathway has been found to affect the evolution of  many 
diseases, including autoimmune diseases, allergic disor-
ders, graft rejection and anti-viral immunity (reviewed 
by[170]). Due to its potent roles in T cell suppression, ga-
lectin-9 has been considered as a therapeutic candidate 
for autoimmune and inflammatory diseases[167,171]. 
Although most studies indicate that TIM-3 is involved 
in galectin-9 mediated signaling in T cells, multiple mech-
anisms and alternative receptors have been also proposed 
for this lectin[163,172,173]. More recently, a publication by 
Leitner et al[174] suggested that TIM-3 does not act as a re-
ceptor for galectin-9. These controversial results empha-
size the involvement of  distinct glycosylated receptors in 
galectin-9 effects. 
In spite of  considerable evidence indicating the role 
of  galectin-9 in tumor biology and inflammation, the 
mechanisms governing expression of  this protein are 
poorly understood. So far, IFN-γ has been shown to in-
duce galectin-9 expression in fibroblasts[175], endothelial 
cells[176] and on Kupffer cell[177]. Additional modulators of  
galectin-9 include interleukin-1β (IL-1β) and interleukin-5 
(IL-5) in astrocytes[178] and eosinophils[179] respectively. In-
terestingly, decreased galectin-9 expression typically cor-
relates with tumor progression and metastasis formation 
in various types of  cancer[166].
Galectin-9 in HCC and in HCV/HBV infection-associated 
HCC
Galectin-9 has been identified as a possible prognostic 
marker in breast cancer, melanoma, and oral squamous 
cell carcinoma[180]. Most recently, Zhang et al[181] examined 
the relationship between galectin-9 expression and HCC, 
using an in vitro approach and immunohistochemistry on 
HCC tissues. The authors found that silencing galectin-9 
expression in HepG2 HCC cells through siRNA-mediat-
ed strategies resulted in a weakened cell aggregation and 
increased proliferation and adhesion to ECM[181]. Also, 
galectin-9 suppression increased tumor cell-endothelial 
cell adhesion and trans-endothelial invasion of  HepG2 
cells. Additionally, downregulation of  galectin-9 in hu-
man HCC tissue specimens represented a significant risk 
factor for patient survival and significantly correlated 
with the histopathologic grade of  the tumor, lymph node 
metastasis, vascular invasion and intrahepatic metasta-
sis[181]. These results emphasized an anti-metastasic role 
for galectin-9 in HCC (Figure 1 and Table 1). 
T-cell responses are regulated by multiple mechanisms 
to maintain homeostasis and to prevent exuberant tis-
sue inflammation and autoimmune disease. Whilst these 
regulatory mechanisms are critical to terminate excessive 
inflammatory responses, they can excessively constrain 
antiviral immunity in settings of  persistent viral infec-
tion[182]. Galectin-9 is present at significantly higher levels 
in sera from patients infected with HCV or HBV com-
pared to normal healthy controls[177,182,183]. Galectin-9 is 
expressed mainly in Kupffer cells[177,182], but is also pres-
ent in inflammatory leucocytes and hepatocytes[183]. Re-
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cently, it has been reported that progression to persistent 
infection of  HCV was accompanied by increased plasma 
levels of  galectin-9[184]. 
In patients chronically infected with HCV or HBV, 
multiple regulatory mechanisms act in concert to induce 
failure of  the immune response and facilitate viral per-
sistence. Interestingly, it has been demonstrated that ga-
lectin-9 plays a key role in limiting T-cell responses in the 
liver and facilitating the establishment of  viral persistence. 
Galectin-9 induces the secretion of  pro-inflammatory 
cytokines from monocytes and macrophages[177] that can 
further amplify immunopathology associated with HCV/
HBV infection. As a counter-effect, galectin-9 induces 
TIM-3-mediated apoptosis of  effector T cells[177,182] and 
favors the expansion of  Tregs[177,184,185] thereby attenuating 
adaptive immune responses. 
Li et al[186] studied the relevance of  galectin-9 in pa-
tients with HBV-associated HCC. By flow cytometry 
analysis, the authors found that tumor cells and T cells 
expressed low amounts of  galectin-9 while dendritic cells 
expressed moderate levels of  this protein and Kupffer 
cells showed the highest expression in HBV-associated 
HCC tissues in comparison to non-tumor adjacent tis-
sues[186]. The authors also observed that in HBV-positive 
patients the percentage of  galectin-9+ Kupffer cells was 
higher in tumor tissues than in normal adjacent tissues. 
However, in HBV-negative patients the expression of  
galectin-9 in Kupffer cells was negligible in both HCC 
and adjacent tissues. Interestingly, IFN-γ derived from 
tumor-infiltrating T cells contributed to the increased ga-
lectin-9 expression in the HCC microenvironment[186]. In 
addition, high numbers of  TIM-3+ T cells were detected 
in HBV-associated HCC, which expressed senescence 
markers and exhibited decreased proliferative ability and 
impaired effector function when compared with TIM-3- 
T cells. Therefore, the TIM-3/galectin-9 signaling axis 
mediates T-cell dysfunction and predicts poor prognosis 
in patients with HBV-associated HCC[186].
Although these data indicates a major role for galec-
tin-9 in regulating liver immune responses, the observa-
tion that this galectin predominantly dampens immune 
function seems hard to reconcile with the poor outcome 
in patients with low galectin-9 expression. Possibly, galec-
tin-9 expression is lost during the course of  tumorigen-
esis, enabling tumor cells to metastasize more easily while 
alternatives modes of  escape are being developed[180] (e.g., 
the up-regulation of  galectin-1) (Figure 1 and Table 1). A 
better understanding of  the mechanisms underlying ga-
lectin-9 functions is required to elucidate its possible role 
as a promising target in HCC. 
Galectin-9 in inflammation-related liver pathologies
The ischemia and reperfusion injury (IRI), an inflam-
matory event controlled by an exogenous antigen-inde-
pendent insult that stimulates innate immunity, remains 
a critical problem in clinical organ transplantation. Liver 
IRI occurs frequently after major hepatic resection or 
liver transplantation. It has been demonstrated that 
CD4+ T cells are the key mediators of  IRI-triggered 
liver inflammation[187]. Kupffer cells release pro-inflam-
matory mediators such as TNF and IL-6[188], and CD4+ 
T cells amplify Kupffer cell activity[189]. In this context, 
blockade of  the TIM-3/galectin-9 pathway exacerbated 
local inflammation and liver damage (Table 2)[190]. These 
results suggest the importance of  TIM-3/galectin-9 
signaling in the maintenance of  liver homeostasis and 
controlling dysregulated liver immune response, for ex-
ample during IRI. 
Similar results were observed in the murine model of  
liver injury, Con A-induced hepatitis, where T cell acti-
vation plays a crucial role. Blockade of  TIM-3 using an 
anti-TIM-3 Ab resulted in more severe liver damage. On 
the contrary, biochemical and histopathological data indi-
cated that a single injection of  galectin-9 was sufficient to 
protect mice against Con A-induced hepatitis (Table 2)[191]. 
Another progressive inflammatory liver disorder is au-
toimmune hepatitis (AIH), where a defective control of  
CD4+ T cells takes place. Liberal et al[192] showed that pa-
tients with AIH had reduced levels of  TIM-3 and galec-
tin-9 on effector CD4+ T cells and Treg cells, respectively, 
as compared to healthy individuals[192]. Reduced signaling 
of  the TIM-3/galectin-9 axis contributed to impaired 
control during AIH by rendering effector cells less prone 
to Treg cell control and Tregs less capable of  suppressing 
effector responses. 
 A distinct subset of  cells, referred as NKT cells has 
been characterized by the expression of  a semi-invariant 
T cell receptor (TCR) and surface antigens typical of  
natural killer (NK) cells. These cells exhibit features of  
both cell types and act as a bridging system between in-
nate and adaptive immunity[193]. NKT cells are particularly 
enriched within the liver and regulate immune responses 
through rapid secretion of  large amounts of  both Th1 
and Th2 cytokines following stimulation[194]. The TIM-3/
galectin-9 signaling pathway also plays a critical role in 
the homeostasis of  hepatic NKT cells. It has been dem-
onstrated that galectin-9 limits the inflammatory response 
in a mouse model of  diet-induced nonalcoholic fatty liver 
disease (NAFLD) (Table 2)[195].
In summary, these observations validated the rel-
evance of  the TIM-3/galectin-9 signaling axis in main-
taining a balanced local immune microenvironment in 
the liver. Dysregulation of  this axis can lead to a chronic 
inflammatory liver disorder which can eventually develop 
into an HCC.
CONCLUSION
Because of  their roles in tumor progression, galectins 
have evolved as promising targets for cancer therapy. A 
variety of  studies revealed the involvement of  this evolu-
tionarily conserved protein family in murine and human 
cancers[26,52-56]. Modified citrus pectin, peptides, anti-ga-
lectin neutralizing antibodies and chemical inhibitors that 
antagonize galectins CRDs have been demonstrated the 
ability to reduce tumor volume, metastasis, angiogenesis, 
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potentiate immune responses and increase host survival 
in various tumor-type models[73,75,196-198]. 
Current literature shows that the “proto-type” ga-
lectin-1, the “chimera” galectin-3 and “tandem-repeat” 
galectin-4 are increased in HCC cells compared to their 
normal counterparts. On the other hand, expression of  
“tandem-repeat” galectin-8 and galectin-9 is decreased 
in tumor hepatocytes. The aberrant expression (up- or 
down-regulation) of  these galectins correlates with tumor 
growth, HCC adhesion, migration and invasion, tumor 
aggressiveness, metastasis, postoperative recurrence and 
poor prognosis (Figure 1 and Table 1). It is noteworthy 
that galectins also play key roles in other liver pathologies 
associated with chronic inflammation and fibrosis (Tables 
2 and 3). Although research in this field is just beginning, 
the role for these galectins in HCC biology is substanti-
ated by a wide range of  accumulating evidence from 
animal models and human samples. Further functional 
studies are crucial to delineate the precise mechanisms 
by which galectins promote liver carcinogenesis, HCC 
progression, aggressiveness, inflammation and metastasis. 
Hopefully, in a near future, galectin-based therapies can 
be developed for the treatment of  HCC, liver-associated 
fibrosis and liver chronic inflammatory disorders.
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